Dimerisation increases the immunogenicity of recombinant Parj1/Parj2 allergens
Open Access
- 1 March 2015
- journal article
- letter
- Published by SAGE Publications in International Journal of Immunopathology and Pharmacology
- Vol. 28 (1) , 142-145
Abstract
Purified recombinant Parj1 and Parj2 allergens bind an IgE repertoire common to the Parietaria species, allowing their use as marker molecules for diagnosis and therapy of allergic disease induced by the Urticaceae family. Preclinical studies on the in vivo immunogenicity of recombinant Parj1, Parj2 and their isoforms indicated differential capacity to induce IgG1 antibody responses, as indication of potential clinical use. A recombinant hetero-dimeric hybrid derivative (PjED), encompassing the shorter Parj1 isoform (Parj1.0201) and Parj2 allergen, was characterised. In vivo immunisation with PjED induces IgG1 antibodies capable of binding all the isoforms of Parietaria major allergens, overcoming the poor immunogenicity of single monomeric allergens. This feature makes PjED a promising candidate molecule to be further characterised for clinical applications in the treatment of Parietaria allergy.Keywords
This publication has 10 references indexed in Scilit:
- An allergen-polymeric nanoaggregate as a new tool for allergy vaccinationInternational Journal of Pharmaceutics, 2014
- Prophylactic and therapeutic vaccination with carrier‐bound Bet v 1 peptides lacking allergen‐specific T cell epitopes reduces Bet v 1‐specific T cell responses via blocking antibodies in a murine model for birch pollen allergyClinical & Experimental Allergy, 2014
- The major allergen of the Parietaria pollen contains an LPS‐binding region with immuno‐modulatory activityAllergy, 2013
- Hypoallergenic Der p 1/Der p 2 combination vaccines for immunotherapy of house dust mite allergyJournal of Allergy and Clinical Immunology, 2012
- Mechanisms underlying allergy vaccination with recombinant hypoallergenic allergen derivativesVaccine, 2012
- Review article: From allergen genes to new forms of allergy diagnosis and treatmentAllergy, 2008
- Recent advances using rodent models for predicting human allergenicityToxicology and Applied Pharmacology, 2005
- Vaccine Engineering Improved by Hybrid TechnologyInternational Archives of Allergy and Immunology, 2004
- The recombinant major allergen of Parietaria judaica and its hypoallergenic variant: in vivo evaluation in a murine model of allergic sensitizationClinical & Experimental Allergy, 2004
- The Allergens of ParietariaInternational Archives of Allergy and Immunology, 2003